Related references
Note: Only part of the references are listed.Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2) : a phase 3, double-blind, randomised, placebo-controlled trial
Eugenio Mercuri et al.
LANCET NEUROLOGY (2022)
Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4
Bram De Wel et al.
JOURNAL OF NEUROLOGY (2021)
An observational cohort study on impact, dimensions and outcome of perceived fatigue in adult 5q-spinal muscular atrophy patients receiving nusinersen treatment
Camilla Binz et al.
JOURNAL OF NEUROLOGY (2021)
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial OfReldesemtivIn Patients With ALS
Jeremy M. Shefner et al.
AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2021)
Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
Robert C. Sergott et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis
Giorgia Coratti et al.
ORPHANET JOURNAL OF RARE DISEASES (2021)
Risdiplam in Type 1 Spinal Muscular Atrophy
Giovanni Baranello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
John W. Day et al.
LANCET NEUROLOGY (2021)
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen
Giorgia Coratti et al.
NEUROMUSCULAR DISORDERS (2021)
Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy
Jerry R. Mendell et al.
JAMA NEUROLOGY (2021)
Nusinersen Wearing-Off in Adult 5q-Spinal Muscular Atrophy Patients
Alma Osmanovic et al.
BRAIN SCIENCES (2021)
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
Basil T. Darras et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec - A Single Centre Experience
Johannes Friese et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2021)
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
Tina Duong et al.
NEUROLOGY-CLINICAL PRACTICE (2021)
Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
Alma Osmanovic et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)
Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy
Haiyan Zhou et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2020)
Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
Tim Hagenacker et al.
LANCET NEUROLOGY (2020)
Recommendations for gene therapy of spinal muscular atrophy with onasemnogene abeparvovec-AVXS-101 Consensus paper of the German representatives of the Society for Pediatric Neurology (GNP) and the German treatment centers with collaboration of the medical scientific advisory board of the German Society for Muscular Diseases (DGM)
Andreas Ziegler et al.
NERVENARZT (2020)
Nusinersen in adult patients with spinal muscular atrophy Observations from a single center
Orly Moshe-Lilie et al.
NEUROLOGY (2020)
Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study
Frederique Audic et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3
Lorenzo Maggi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy
Crystal Jing Jing Yeo et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2020)
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data
Marika Pane et al.
ANNALS OF NEUROLOGY (2019)
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
Stefan Sturm et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients
Claudia D. Wurster et al.
JOURNAL OF NEUROLOGY (2019)
The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy
Heidemarie Kletzl et al.
NEUROMUSCULAR DISORDERS (2019)
Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3-A Prospective Observational Study
Maggie C. Walter et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
One Year of Newborn Screening for SMA - Results of a German Pilot Project
Katharina Vill et al.
JOURNAL OF NEUROMUSCULAR DISEASES (2019)
The role of survival motor neuron protein (SMN) in protein homeostasis
Helena Chaytow et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2018)
Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
Richard S. Finkel et al.
NEUROMUSCULAR DISORDERS (2018)
Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2018)
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
E. Mercuri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
Hasane Ratni et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 A cohort study
Karolina Aragon-Gawinska et al.
NEUROLOGY (2018)
Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial)
Marloes Stam et al.
BMJ OPEN (2018)
Survival of motor neurone protein is required for normal postnatal development of the spleen
Alison K. Thomson et al.
JOURNAL OF ANATOMY (2017)
Clinical studies of RG7916 in patients with spinal muscular atrophy: SUNFISH part 1 study update
E. Mercuri et al.
NEUROMUSCULAR DISORDERS (2017)
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
J. R. Mendell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
R. S. Finkel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy a literature review
Ingrid E. C. Verhaart et al.
ORPHANET JOURNAL OF RARE DISEASES (2017)
Effect of Salbutamol on Respiratory Muscle Strength in Spinal Muscular Atrophy
Sonia Khirani et al.
PEDIATRIC NEUROLOGY (2017)
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
Richard S. Finkel et al.
LANCET (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy
Eric W. Ottesen et al.
SCIENTIFIC REPORTS (2016)
SMN deficiency disrupts gastrointestinal and enteric nervous system function in mice
Sara E. Gombash et al.
HUMAN MOLECULAR GENETICS (2015)
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai A. Naryshkin et al.
SCIENCE (2014)
Glucose metabolism and pancreatic defects in spinal muscular atrophy
Melissa Bowerman et al.
ANNALS OF NEUROLOGY (2012)
Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of > 72 400 specimens
Elaine A. Sugarman et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2012)
Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
Yimin Hua et al.
NATURE (2011)
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Marco A. Passini et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Cardiac defects contribute to the pathology of spinal muscular atrophy models
Monir Shababi et al.
HUMAN MOLECULAR GENETICS (2010)
Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
Kevin D. Foust et al.
NATURE BIOTECHNOLOGY (2010)
Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy
Srinivasan Shanmugarajan et al.
JOURNAL OF PATHOLOGY (2009)
Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
Arthur H. M. Burghes et al.
NATURE REVIEWS NEUROSCIENCE (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Enhancement of SMN2 Exon 7 inclusion by antisense oligonucleotides targeting the exon
Yimin Hua et al.
PLOS BIOLOGY (2007)
Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron
NK Singh et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Share Paper
